Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)
| Market Cap | $6.28B+35.5% |
| Revenue (ttm) | $670.78M+42.2% |
| Net Income | -$903.88M-2082.1% |
| EPS | -$15.23-1673.0% |
| Shares Out | 65.28M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,062,250 |
| Open | $94.50 |
| Previous Close | $95.51 |
| Day's Range | $94.10 - $98.39 |
| 52-Week Range | $63.23 - $130.00 |
| Beta | 0.49 |
| Analysts | Buy |
| Price Target | $155.80(+62.07%) |
| Earnings Date | Feb 24, 2027 |
About MIRM
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
11 firms rating MIRM in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 24, 2027Earnings report
$MIRM stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in MIRM holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by MIRM's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
MIRM Estimated quarterly lobbying spending
Source: U.S. Senate LDA
MIRM Revenue by Segment or Geography
| Product sales, net | $185.72M | 80.06% |
| Stock-based compensation | $32.76M | 14.12% |
| Acquired IPR&D | $13.50M | 5.82% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New MIRM patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to MIRM from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in MIRM
| XBIState Street SPDR S&P Biotech ETF | $120.31M |
| VTIVanguard Morningstar Total Stock Market ETF | $119.00M |
| IWMiShares Russell 2000 ETF | $118.89M |
| VBVanguard Morningstar Small-Cap ETF | $105.23M |
| VBKVanguard Morningstar Small-Cap Growth ETF | $58.89M |
| VXFVanguard Extended Market ETF | $53.94M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from MIRM’s recent data — informational, not investment advice
What’s Behind the Score
News check: Brelovitug achieved second Phase III win with primary endpoint met in AZURE-4; advancing toward BLA filing for hepatitis delta treatment.
Recent Insider Activity
Insider Score Trend Over Time
-34.0 since Aug 21Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| LFSC | F/M Emerald Life Sciences Innovation ETF | 3.64% |
| TDNA | T. Rowe Price Biotech ETF | 1.89% |
| BBP | Virtus Biotech ETF | 1.22% |
| XBI | State Street SPDR S&P Biotech ETF | 1.16% |
| ILDR | First Trust Innovation Leaders ETF | 1.01% |
| BRES | Burney U.S. Equity Select ETF | 0.87% |
| SCDS | JPMorgan Fundamental Data Science Small Core ETF | 0.45% |
| AIMS | Acuitas Small Cap Active ETF | 0.43% |
| BRSM | MFS Blended Research Small-Mid Cap ETF | 0.39% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.39% |
| EHLS | Even Herd Long Short ETF | 0.39% |
| ESSC | Eventide Small Cap ETF | 0.39% |
Weight is the stock’s share of each fund’s holdings.
